DiscoveRX, GSK & MRCT collaborate to de-orphanise GPCRs

DiscoveRX, GSK & MRCT collaboration to de-orphanise GPCRs mentioned in an article about universities driving new technology…

Bicycle Therapeutics is new MRC spinout

The spin out is a new biotechnology company developing a novel technology platform for the creation of a new generation of biotherapeutics, has secured seed funding from Atlas Venture and Novartis Venture Fund. Bicycle Therapeutics combines the most desirable features of small molecules and biologics, to create highly specific and highly stable drugs.

DiscoveRX GSK and MRCT collaborate to deorphanise GPCRs

The three way alliance aims to seek out natural substances that bind to G-protein-coupled receptors (GPCRs). Through the identification of the natural ligand for these receptors it is anticipated that this work will identify and validate new drug targets that could ultimately help develop new therapies, as compounds that modulate GPCRs are already the basis of many licensed medicines.

Centre for Therapeutics Discovery

A major centre to fast-track the discovery and development of novel drugs will be created by the Medical Research Council (MRC) and MRC Technology (MRCT).

Heptares secures funding

Heptares has raised GBP21 million (US$30 million) of equity finance in a successful Series A private round from three blue-chip international venture capital firms. Clarus Ventures led the syndicate, which includes the founding investor, MVM Life Science Partners, and the Novartis Option Fund. All three investors contributed equally.

UK Drug Discovery Consortium symposium

‘Imperial College London‘, ‘Cancer Research UK Centre for Cancer Therapeutics at The Institute of Cancer Research’, ‘ Drug Discovery Unit, University of Dundee’, ‘Cancer Research Technology (CRT)’, ‘MRC Technology’ and the ‘Wellcome Trust’, members of the new UK Drug Discovery Consortium, have announced their first symposium “21st Century Drug Discovery – a new approach” on March 11th, 2009 in central London.

MRCT licence rights to develop potential novel immunotherapy

Centocor Ortho Biotech have signed agreements for the development of a novel immunotherapy targeting respiratory disease. The potential therapy was identified and characterised at the world famous MRC Laboratory of Molecular Biology as part of a basic research programme. This research was quickly identified as having therapeutic potential. Further work was performed by MRCT’s Drug Discovery Group in a prime example of translational research.